SYK - Stryker Corporation (SYK) Q1 2024 Earnings Call Transcript
2024-04-30 20:30:10 ET
Start Time: 16:30
End Time: 17:28
Stryker Corporation (SYK)
Q1 2024 Earnings Conference Call
April 30, 2024, 16:30 PM ET
Company Participants
Kevin Lobo - Chair and CEO
Glenn Boehnlein - VP and CFO
Jason Beach - VP, Finance and IR
Conference Call Participants
Robert Marcus - JPMorgan
Lawrence Biegelsen - Wells Fargo Securities
Ryan Zimmerman - BTIG
Joanne Wuensch - Citibank
Pito Chickering - Deutsche Bank
Shagun Singh Chadha - RBC Capital
Vijay Kumar - Evercore
Travis Steed - Bank of America
Matthew O'Brien - Piper Sandler
Matt Miksic - Barclays
Danielle Antalffy - UBS
Matt Taylor - Jefferies
Caitlin Cronin - Canaccord
Sam Brodovsky - Truist
Joshua Jennings - Cowen
Andrew Ranieri - Morgan Stanley
Presentation
Operator
Welcome to the First Quarter 2024 Stryker Earnings Call. My name is Christine, and I'm your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes.
Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.
I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.
Kevin Lobo
Welcome to Stryker's first quarter earnings call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Jason Beach, Vice President of Finance and Investor Relations. For today's call, I will provide opening comments followed by Jason with the trends we saw during the quarter as well as some product updates. Glenn will then provide additional details regarding our quarterly results before we open the call to Q&A.
In the first quarter, we delivered organic sales growth of 10% with double-digit growth in MedSurg and Neurotechnology and high single digit growth in Orthopaedics and Spine, despite one less selling day and tough comparables from a year ago. This reflects our team's continued strong commercial execution. Our results were led by very strong U.S. performance, notably in Instruments, Medical, Endoscopy, Trauma and Extremities and Mako. ...
Stryker Corporation (SYK) Q1 2024 Earnings Call Transcript